Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …
isolates are frequent causes of serious nosocomial infections that may compromise the …
Epidemiology of β-lactamase-producing pathogens
K Bush, PA Bradford - Clinical microbiology reviews, 2020 - Am Soc Microbiol
SUMMARY β-Lactam antibiotics have been widely used as therapeutic agents for the past
70 years, resulting in emergence of an abundance of β-lactam-inactivating β-lactamases …
70 years, resulting in emergence of an abundance of β-lactam-inactivating β-lactamases …
[HTML][HTML] Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity
and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of …
and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of …
Metallo-β-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design
G Bahr, LJ Gonzalez, AJ Vila - Chemical reviews, 2021 - ACS Publications
Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …
spread of genes coding for resistance determinants among bacteria challenges the use of …
It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa
Pseudomonas aeruginosa is the most frequent cause of infection among non-fermenting
Gram-negative bacteria, predominantly affecting immunocompromised patients, but its …
Gram-negative bacteria, predominantly affecting immunocompromised patients, but its …
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
Pseudomonas aeruginosa is an opportunistic pathogen affecting immunocompromised
patients. It is known as the leading cause of morbidity and mortality in cystic fibrosis (CF) …
patients. It is known as the leading cause of morbidity and mortality in cystic fibrosis (CF) …
Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance
T Sawa, K Kooguchi, K Moriyama - Journal of intensive care, 2020 - Springer
Along with the recent spread of multidrug-resistant bacteria, outbreaks of extended-spectrum
β-lactamase (ESBL) and carbapenemase-producing bacteria present a serious challenge to …
β-lactamase (ESBL) and carbapenemase-producing bacteria present a serious challenge to …
The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria
D Hammoudi Halat, C Ayoub Moubareck - Antibiotics, 2020 - mdpi.com
Carbapenemases are β-lactamases belonging to different Ambler classes (A, B, D) and can
be encoded by both chromosomal and plasmid-mediated genes. These enzymes represent …
be encoded by both chromosomal and plasmid-mediated genes. These enzymes represent …
Envelope structures of Gram-positive bacteria
M Rajagopal, S Walker - Protein and sugar export and assembly in Gram …, 2017 - Springer
Gram-positive organisms, including the pathogens Staphylococcus aureus, Streptococcus
pneumoniae, and Enterococcus faecalis, have dynamic cell envelopes that mediate …
pneumoniae, and Enterococcus faecalis, have dynamic cell envelopes that mediate …
Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa
KM Kazmierczak, S Rabine, M Hackel… - Antimicrobial agents …, 2016 - Am Soc Microbiol
ABSTRACT Metallo-β-lactamases (MBLs) hydrolyze all classes of β-lactams except
monobactams and are not inhibited by classic serine β-lactamase inhibitors. Gram-negative …
monobactams and are not inhibited by classic serine β-lactamase inhibitors. Gram-negative …